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Abstract It is well-known that male breast cancer (MBC)
susceptibility is mainly due to high-penetrance BRCA1/2
mutations. Here, we investigated whether common low-
penetrance breast cancer (BC) susceptibility alleles may
influence MBC risk in Italian population and whether variant
alleles may be associated with specific clinicopathological
features of MBCs. In the frame of the Italian Multicenter
Study on MBC, we genotyped 413 MBCs and 745 age-
matched male controls at 9 SNPs annotating known BC
susceptibility loci. By multivariate logistic regression mod-
els, we found a significant increased MBC risk for 3 SNPs, in
particular, with codominant models, for rs2046210/ESR1
(OR = 1.71; 95 % CI: 1.43–2.05; p = 0.0001), rs3803662/
TOX3 (OR = 1.59; 95 % CI: 1.32–1.92; p = 0.0001), and
rs2981582/FGFR2 (OR = 1.26; 95 % CI: 1.05–1.50;
p = 0.013). Furthermore, we showed that the prevalence of
the risk genotypes of ESR1 tended to be higher in ER-
tumors (p = 0.062). In a case–case multivariate analysis, a
statistically significant association between ESR1 and ER-
tumors was found (OR = 1.88; 95 % CI: 1.03–3.49;
p = 0.039). Overall, our data, based on a large and well-
characterized MBC series, support the hypothesis that
common low-penetrance BC susceptibility alleles play a role
in MBC susceptibility and, interestingly, indicate that ESR1
is associated with a distinct tumor subtype defined by
ER-negative status.
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Introduction
Breast cancer (BC) does affect not only women but also
men, although rarely. In Western countries, male breast
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cancer (MBC) makes up less than 1 % of all BCs and less
than 1 % of all cancers in men [1, 2]. Its incidence is
estimated at 1.1 per 100,000 men a year [3]; however,
recent epidemiologic studies suggest that the incidence of
MBC is increasing by 1.1 % yearly [1, 2]. In Italy, inci-
dence rates, standardized on the European population, are
about 1.2 new cases per 100,000 men per year and around
450 men with BC are estimated to be diagnosed in 2011
[4].
Similar to female BC (FBC), MBC is likely to be caused
by the concurrent effects of different risk factors, including
hormonal, environmental, and genetic risk factors [5].
Family history of BC and personal history of cancer are
frequently observed in MBC patients [6], thus pointing to a
relevant genetic component in MBC predisposition. Muta-
tions in the two major high-penetrance BC genes, BRCA1
and, mainly, BRCA2, play the most relevant role in MBC
susceptibility [6, 7]. Rare variants in moderate-penetrance
BC susceptibility genes, including CHEK2, BRIP1, PALB2,
and RAD51C, may also play a role in MBC, although at
lower extent [7]. We recently reported that only a small
proportion (about 14 %) of MBCs is accounted by high- and
moderate penetrance BC susceptibility genes in Italy
[8–10]. Thus, much of the genetic contribution to MBC risk
remains to be elucidated.
According to the ‘‘polygenic’’ model, the genetic sus-
ceptibility to BC can be attributed to the combined effects
of common low-penetrance susceptibility alleles, each
conferring a small effect on BC risk and explaining a high
proportion of cancers that may arise in a genetically sus-
ceptible minority [11, 12]. Genome-wide association stud-
ies (GWAS) have identified associations between single
nucleotide polymorphisms (SNPs), acting as common low-
penetrance variant alleles, and BC risk in women [13–21].
An involvement of some of the SNPs found to be associated
with FBC has been suggested in MBC susceptibility [22],
and by GWAS we could recently identify a novel common
variant associated with MBC [23].
Recent studies show that common low-penetrance BC
susceptibility alleles may modify the risk associated with
BRCA1 and BRCA2 mutations in FBC, thus indicating a
role of low penetrance alleles as modulators of the risk
conferred by high-penetrance BC susceptibility genes [24].
At present, there are no data whether low-penetrance BC
susceptibility alleles may modulate BC in BRCA1/2 male
carriers.
In addition, there is evidence that the increased risk
associated with several of the loci identified to date shows
BC subtype specificity in FBC [25–28]. Notably, associa-
tions with most of the susceptibility loci appear to be
stronger for estrogen receptor-positive (ER?) rather than
for ER-negative (ER-) BCs [25]. In particular, variants in
CASP8, 5p12, FGFR2 show the strongest evidence of
association with ER? tumors whereas variants in 2q35,
MAP3K1, LSP1, TOX3 are associated with both ER? and
ER- disease [25, 27]. On the other hand, variants in ESR1
and 19p13 show evidence of an association primarily with
ER- BCs [20, 29–31]. At present, there are no data on
possible correlations between clinicopathological charac-
teristics and common low-penetrance BC susceptibility
alleles in MBC.
Compared with FBC, MBC more often displays ER?
and progesterone receptor-positive (PR?) status [3]. We
recently showed that BRCA2-related MBCs represent a
subgroup of tumors with a peculiar phenotype character-
ized by high tumor grade, the absence of PR expression and
HER2 positive status [10], thus providing evidence that
high-penetrance genetic factors can also influence tumor
type in MBC. This raises the possibility that other sus-
ceptibility loci may also be associated with specific sub-
types of MBC.
Here, taking advantage of the ongoing Italian Multi-
center Study on MBC, we conducted a case–control study
of a large series of well-characterized MBC cases and
matched controls to evaluate the impact of common low-
penetrance BC alleles in Italian MBC patients and to assess
whether common BC alleles may be associated with spe-
cific clinicopathological features of MBCs.
Materials and methods
Study population
The study was performed comparing a series of 413 MBC
patients and 745 healthy age-matched male controls. All
subjects were recruited from ten Italian Investigation Centers
distributed across the country in the frame of the ongoing
Italian Multicenter Study on MBC [10]. Information collected
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for each MBC case included: age at diagnosis, family and
personal history of cancer, recurrence of the disease, BRCA1/2
mutation status, tumor histological type, grade (G), node
(N) status, ER, PR, Ki-67, and HER2 expression. Control
samples were obtained from individuals enrolled under
research or clinical protocols and from blood donors. All
control individuals were Caucasians and residing in the same
areas of cases. In addition, 198 unaffected male BRCA1/2
carriers were included into the study as a separate control
group. The study was approved by the local ethical
committees.
Blood collection and DNA extraction/genotyping
From each study participant blood or DNA samples were
obtained. DNA was extracted from peripheral blood lym-
phocytes using QIAamp DNA Blood mini kit (Qiagen,
Venlo, The Netherlands), following manufacturer instruc-
tions. DNA samples were quantified using NanoDrop 1000
(Thermo Fisher Scientific, Waltham, Massachusetts, USA).
MBC cases and controls were genotyped by allelic-
discrimination real-time PCR with TaqMan probes in ABI
7500 fast real-time PCR instrument (Life Technologies,
Carlsbad, California, USA) at 2q35 rs13387042, CASP8
rs1045485, 5p12 rs10941679, MAP3K1 rs889312, ESR1
rs2046210, FGFR2 rs2981582, LSP1 rs3817198, TOX3
rs3803662, and 19p13 rs2363956 by commercially avail-
able assays from Life Technologies (Carlsbad, California,
USA), according to the manufacturer’s instruction.
Statistical analyses
The genotype frequencies for each individual DNA poly-
morphism were evaluated in both series of cases and
controls, and deviations from Hardy–Weinberg equilibrium
in controls were assessed by a Chi-square test with one
degree of freedom.
Considering a minor allele frequency of 11 % (lower
value in our control’s series) and a dominant model, with a
case–control ratio of 1:1.8 (413 cases and 756 controls), we
could identify an odds ratio (OR) of 1.59 with a power of
90 % and a = 0.05.
Chi-square test was used to evaluate the difference of
specific parameters between different groups of cases.
Logistic regression models, adjusted for enrollment center
and age of participants, were performed to assess the
association between each DNA polymorphism and overall
MBC risk by ORs and their 95 % confidence intervals
(CIs). For each gene, a specific model was used to evaluate
separately the effect of the heterozygous genotype and of
the homozygous variant. In each model, the common
homozygote genotype (in the control population) was
considered as the reference category. We also evaluated the
MBC risk by separate logistic regression models based on
different inheritance model: dominant, recessive, and
multiplicative codominant effect.
To evaluate the potential associations between genetic
susceptibility and specific MBC clinicopathological char-
acteristics, multinomial regression logistic analyses,
including the enrollment center and age of participants,
were performed by stratifying MBC cases according to ER/
PR combined status and tumor subtypes. The analyses were
carried out using three different models based on dominant,
recessive, or codominant effect.
A p value\0.05 was considered statistically significant.
All the analyses were performed using SAS (SAS/STAT
version 9.1) statistical program.
Results
The clinicopathological features of the 413 MBC included
in this study are summarized in Table 1. Age at first MBC
diagnosis ranged between 22 and 90 years, with a mean
age of 61.3 years (SD 11.8). 160 cases (38.7 %) reported a
family history (FH) of breast and/or ovarian cancer in first-
degree relatives and 62 cases (15 %) a personal history of
other cancers. 17 cases (4.1 %) reported a contralateral BC.
With regard to BRCA1/2 mutation status, 3 MBCs carried
BRCA1 (0.7 %) and 49 BRCA2 mutations (11.9 %). Male
breast tumors were more often invasive ductal carcinomas
(85.5 %), G2 (56.4 %) and with stage I–II of the disease
(77.7 %), 57.7 % of the cases showed negative node status
(N-) and 54.8 % low proliferative activity (Ki-67 low). As
shown in Table 2, the majority of tumors were ER?
(91.9 %), PR? (84.7 %) and HER2- (75 %); 83 % of
MBCs were ER?/PR? tumors and 69.6 % were Luminal
A (ER and/or PR?, HER2-) subtype.
All MBC cases and controls were genotyped at nine SNPs
(rs13387042/2q35, rs1045485/CASP8, rs10941679/5p12,
rs889312/MAP3K1, rs2046210/ESR1, rs2981582/FGFR2,
rs3817198/LSP1, rs3803662/TOX3, and rs2363956/19p13)
annotating the strongest BC associated loci that showed
association with tumor subtype defined by hormone receptor
status. Genotype distribution was consistent with Hardy–
Weinberg equilibrium among controls.
Estimates for the association between the nine SNPs
evaluated and overall BC risk are shown in Table 3. When
we compared 413 MBC cases with 745 age-matched male
controls, statistically significant associations emerged by
separate logistic regression models, adjusted for center of
enrollment and age of participants, between overall MBC
risk and three SNPs: rs2046210/ESR1, rs2981582/FGFR2,
and rs3803662/TOX3. In particular, based on a codominant
model, the following ORs were found: ESR1 OR = 1.71
(95 % CI: 1.43–2.05; p = 0.0001), TOX3 OR = 1.59 (95 %
Breast Cancer Res Treat (2013) 138:861–868 863
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CI: 1.32–1.92; p = 0.0001), and FGFR2 OR = 1.26 (95 %
CI: 1.05–1.50; p = 0.013). Similar results also emerged by
separate regression analyses based on dominant or recessive
models for ESR1 (p = 0.0001 in both cases) and TOX3
(p = 0.0001 in both cases), while for FGFR2 we found a
significant effect (p = 0.03) with the dominant model and a
borderline effect (p = 0.058) with the recessive model (data
not shown).
We also evaluated the association between the nine SNPs
and overall MBC risk after exclusion of the 52 MBC carriers
of germ-line BRCA1/2 mutations and obtained the same
significant associations with the three above mentioned
SNPs. In particular, we found a significant effect for ESR1
(p = 0.0001), TOX3 (p = 0.0001), and FGFR2 (p = 0.004)
with codominant models (data not shown). We then com-
pared the 52 BRCA1/2 carriers in the MBC series with the
additional control group of 198 unaffected male BRCA1/2
carriers, a statistically significant association (p = 0.02;
OR = 2.51; 95 % CI 1.16–5.43) between increased MBC
risk and ESR1 risk genotype emerged (data not shown).
We further analyzed the distribution of the three SNPs
associated with overall MBC risk according to tumor
receptor status in the series of MBC cases (Table 4). The
prevalence of the risk genotypes of ESR1 tended to be
higher in ER- subgroup (pChi-square = 0.062). As shown in
Table 4, a statistically significant association between
ESR1 and ER- tumors emerged in a case–case multivari-
ate analysis adjusted for center of enrollment and age of
patients (OR = 1.88; 95 % CI: 1.03–3.49; p = 0.039).
When tumors were classified according to the co-expres-
sion of ER and PR status, the prevalence of the risk
genotypes of ESR1 tended to be higher in ER-/PR-
tumors versus ER?/PR? tumors (pChi-square = 0.11). As
Table 1 Clinicopathological characteristics of the 413 MBC cases
Characteristics N %
Age at diagnosis
\50 68 16.5
50–70 254 61.5
[70 91 22.0
First degree family history of breast/ovarian cancer
Negative 253 61.3
Positive 160 38.7
Personal history of other cancers
Negative 351 85.0
Positive 62 15.0
Contralateral BC
No 396 95.9
Yes 17 4.1
BRCA1/2 mutation status
BRCA1 mutation positive 3 0.7
BRCA2 mutation positive 49 11.9
BRCA1/2 wild-type 361 87.4
Histologya
Invasive ductal carcinoma 283 85.5
In situ ductal carcinoma 26 7.9
Medullary carcinoma 2 0.6
Lobular carcinoma 4 1.2
Other 16 4.8
Gradinga
1 37 12.4
2 168 56.4
3 93 31.2
Stagea
I 104 41.4
II 91 36.3
III 48 19.1
IV 8 3.2
Node statusa
Negative 162 57.7
Positive 119 42.3
Ki-67a
Low 131 54.8
High 108 45.2
a Some data for each characteristic are not available
Table 2 Receptor status and tumor subtypes of the 413 MBC cases
Characteristicsa N %
ER
Negative 26 8.1
Positive 295 91.9
PR
Negative 49 15.3
Positive 271 84.7
HER2
Negative 183 75.0
Positive 61 25.0
ER/PR
-/- 21 6.6
-/? 5 1.6
?/- 28 8.8
?/? 266 83.0
Subtype
Luminal A 167 69.6
Luminal B 56 23.3
HER2? 5 2.1
Triple negative 12 5.0
Luminal A ER and/or PR?, HER2-, Luminal B ER and/or PR?,
HER2?, Her2? ER-, PR-, HER2?, Triple negative ER-, PR-,
HER2-
a Some data for each characteristic are not available
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shown in Table 5, in a case–case analysis using a poly-
nomial regression approach including terms for center of
enrollment, age of patients and genotype (codominant
model), this association failed to reach the level of statis-
tical significance (OR = 1.90; 95 % CI: 0.98–3.71;
p = 0.057). No significant differences in the distribution of
the risk genotypes of FGFR2 and TOX3 according to
combined ER/PR receptor status were found.
No significant differences in the distribution of the risk
genotype of ESR1 were observed in the case series classified
by Luminal A (ER and/or PR?, HER2), Luminal B (ER and/
or PR?, HER2?), HER2? (ER-, PR-, HER2?), and triple
negative (ER-, PR-, HER2-) tumor subtypes (Supple-
mentary Table 1).
Although detailed subgroup analyses were precluded by
small numbers, it is interesting to note that the HER2?
Table 3 Distribution of 413 cases and 745 controls according to genotype frequenciesa and MBC risk estimates for selected susceptibility SNPsb
SNP Chromosome Gene Genotype Cases N (%) Controls N (%) OR (95 % CI) p valuec
rs13387042 2q35 GG 83 (20.1) 163 (21.9) 1
GA 189 (45.8) 366 (49.1) 0.96 (0.69–1.34) 0.82
AA 141 (34.1) 216 (29.0) 1.13 (0.94–1.34) 0.19
Codominant model 1.14 (0.96–1.37) 0.14
rs1045485 2q33.1 CASP8 GG 324 (78.6) 587 (78.8) 1
GC 82 (19.9) 150 (20.1) 1.01 (0.74–1.39) 0.93
CC 6 (1.5) 8 (1.1) 1.27 (0.72–2.24) 0.41
Codominant model 1.06 (0.80–1.41) 0.68
rs10941679 5p12 AA 226 (54.9) 427 (57.3) 1
AG 160 (38.8) 273 (36.6) 1.13 (0.87–1.48) 0.37
GG 26 (6.3) 57 (6.1) 1.09 (0.83–1.42) 0.55
Codominant model 1.11 (0.90–1.36) 0.33
rs889312 5q11.2 MAP3K1 AA 183 (44.3) 371 (49.8) 1
AC 200 (48.4) 318 (42.7) 1.26 (0.97–1.64) 0.08
CC 30 (7.3) 56 (7.5) 1.10 (0.85–1.41) 0.47
Codominant model 1.17 (0.96–1.43) 0.11
rs2046210 6q25.1 ESR1 CC 109 (26.5) 324 (43.5) 1
CT 212 (51.5) 318 (42.7) 1.94 (1.45–2.59) 0.0001
TT 91 (22.0) 103 (13.8) 1.72 (1.42–2.08) 0.0001
Codominant model 1.71 (1.43–2.05) 0.0001
rs2981582 10q26.13 FGFR2 GG 110 (26.6) 245 (32.9) 1
GA 205 (49.6) 361 (48.5) 1.28 (0.95–1.72) 0.10
AA 98 (23.8) 139 (18.7) 1.26 (1.05–1.51) 0.013
Codominant model 1.26 (1.05–1.50) 0.013
rs3817198 11p15.5 LSP1 TT 186 (45.1) 331 (44.4) 1
TC 174 (42.2) 334 (44.8) 0.90 (0.69–1.18) 0.46
CC 52 (12.7) 80 (10.8) 1.09 (0.88–1.35) 0.43
Codominant model 1.02 (0.85–1.23) 0.83
rs3803662 16q12.1 TOX3 CC 143 (34.7) 352 (47.2) 1
CT 195 (47.3) 323 (43.4) 1.45 (1.10–1.91) 0.008
TT 74 (18.0) 70 (9.4) 1.65 (1.35–2.01) 0.0001
Codominant model 1.59 (1.32–1.92) 0.0001
rs2363956 19p13 GG 112 (27.2) 223 (29.9) 1
GT 213 (51.7) 374 (50.2) 1.13 (0.84–1.52) 0.41
TT 87 (21.1) 148 (19.9) 1.07 (0.89–1.28) 0.49
Codominant model 1.07 (0.89–1.28) 0.46
a Some genotypes were not available for the whole series of cases and controls
b ORs and 95 % CI for specific genotypes and codominant model were calculated using separate logistic regression models adjusted for
enrollment’s center and age of study subjects
c p values \0.05 in bold text; p values 0.05–0.10 in italics
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MBC subtype (five cases) showed the highest percentage
(60 %) of the risk genotype of ESR1, and that three out of
these five MBCs harbored a BRCA2 mutation. In a case–
case analysis using a polynomial regression approach,
including terms for center of enrollment, age of patients,
and genotype (co-dominant model), this association was
not significant (p = 0.067). No significant differences in
the distribution of the risk genotypes of FGFR2 and TOX3
according to cancer subtype was observed.
Finally, we evaluated the distribution of ESR1, FGFR2,
and TOX3 genotypes in the MBC series according to selected
tumor characteristics, such as grade, stage, nodal involvement,
and proliferative activity, and no significant differences in
genotype distribution emerged (Supplementary Table 2).
Discussion
We have shown that common low-penetrance BC suscep-
tibility alleles modulate MBC risk in the Italian population
examined in this study, and, interestingly, that these alleles
are associated with increased risk of specific breast tumor
subtypes.
Three of the nine SNPs genotyped in our series (rs2046210/
ESR1, rs2981582/FGFR2 and rs3803662/TOX3) showed
statistically significant associations with overall MBC risk. In
Table 4 Distribution of the three SNPs associated with overall MBC risk in the case’s series according to ER, PR, and HER2 status, and
p values of the association with specific MBC subtypes
ER PR HER2
- ? - ? - ?
(n = 26) (n = 295) (n = 49) (n = 271) (n = 183) (n = 61)
N (%) N (%) N (%) N (%) N (%) N (%)
ESR1
CC 4 (15.4) 82 (27.8) 10 (20.4) 76 (28.0) 47 (25.7) 15 (24.6)
CT 12 (46.1) 155 (52.5) 26 (53.1) 140 (51.7) 97 (53.0) 33 (54.1)
TT 10 (38.5) 58 (19.7) 13 (26.5) 55 (20.3) 39 (21.3) 13 (21.3)
p valuea 0.039 0.25 0.98
FGFR2
GG 5 (19.2) 78 (26.4) 11 (22.4) 72 (26.6) 39 (21.3) 17 (27.9)
GA 12 (46.2) 146 (49.5) 27 (55.2) 130 (48.0) 94 (51.4) 26 (42.6)
AA 9 (34.6) 71 (24.1) 11 (22.4) 69 (25.4) 50 (27.3) 18 (29.5)
p valuea 0.26 0.96 0.74
TOX3
CC 9 (34.6) 94 (31.9) 18 (36.7) 85 (31.3) 55 (30.1) 23 (37.7)
CT 11 (42.3) 147 (49.8) 20 (40.8) 137 (50.6) 97 (53.0) 27 (44.3)
TT 6 (23.1) 54 (18.3) 11 (22.5) 49 (18.1) 31 (16.9) 11 (18.0)
p valuea 0.89 0.92 0.49
a p value from separate logistic regression models including terms for enrollment’s center, age of patients and genotype (codominant). p values
\0.05 in bold text
Table 5 Distribution of the three SNPs associated with overall MBC
risk in the case’s series according to combined ER/PR status, and
p values of the association with specific MBC risk
ER?/PR? ER-/PR- ER-/PR? ER?/PR-
(n = 266) (n = 21) (n = 5) (n = 28)
N (%) N (%) N (%) N (%)
ESR1
CC 75 (28.2) 3 (14.3) 1 (20.0) 7 (25.0)
CT 138 (51.9) 10 (47.6) 2 (40.0) 16 (57.1)
TT 53 (19.9) 8 (38.1) 3 (40.0) 5 (7.9)
p valuea 0.057 0.39 0.99
FGFR2
GG 70 (26.3) 3 (14.3) 2 (40.0) 8 (28.6)
GA 128 (48.1) 10 (47.6) 2 (40.0) 17 (60.7)
AA 68 (25.6) 8 (38.1) 1 (20.0) 3 (10.7)
p valuea 0.14 0.54 0.19
TOX3
CC 84 (31.6) 8 (38.1) 1 (20.0) 10 (35.7)
CT 135 (50.8) 9 (42.9) 2 (40.0) 11 (39.3)
TT 47 (17.6) 4 (19.0) 2 (40.0) 7 (25.0)
p valuea 0.72 0.30 0.82
a p value from multinomial regression logistic models including
terms for enrollment’s center, age of patients and genotype (codom-
inant). The reference category is the group of cases ‘‘ER?/PR?’’ in
each model. p values 0.05–0.10 in italics
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particular, ESR1 and TOX3 showed the strongest association.
Notably, we recently reported a strong association for TOX3
and ESR1 with increased MBC risk in a large collaborative
series [23]. In particular, TOX3 reached a genome wide-sig-
nificance and showed an association stronger in males than
that in females, while ESR1 was validated in the same series
[22, 23]. In contrast, FGFR2 did not emerge in such analysis.
Added value of the present study is that all MBC cases
analyzed here were characterized for BRCA1/2 mutation
status, including 52 MBC BRCA1/2 carriers, and that we
could examine a control series of 198 unaffected male
BRCA1/2 carriers. This allowed us to show that low-pen-
etrance alleles, associated with increased risk of BC in the
general population, may also modify the risk of developing
BC in male BRCA1/2 mutation carriers. At present, there
are no data whether low-penetrance susceptibility alleles
may modulate BC risk in male BRCA1/2 carriers. Notably,
we showed that rs2046210/ESR1 was associated with
increased MBC risk in analyses restricted to BRCA1/2 male
carriers, suggesting that it may act as a genetic modifier of
BRCA genes in MBC. Although based on a relatively small
series, our data suggest that common BC susceptibility
alleles might modulate the risk of BC in BRCA male car-
riers, as known in female carriers [24]. Large collaborative
studies on BRCA1/2 male carriers are needed to validate
our results.
Furthermore, our well-characterized MBC series
enabled us to carry out a more detailed analysis revealing
that the relative risk associated with common genetic
variants may also be linked to clinically important char-
acteristics of tumors defined by hormonal receptor status.
At present, there are no data on possible correlations
between clinicopathological characteristics and common
low-penetrance BC susceptibility alleles in MBC. On the
other hand, in FBC, there is increasing evidence that
associations between common variants and BC risk could
vary by clinically important tumor characteristics, mainly
by ER expression [25–31]. We found that ESR1 was sig-
nificantly associated with the risk of ER- BCs in males.
Intriguingly, ESR1 locus has also been associated with
bone mineral density, a phenotype that is affected by
estrogens [32]. Interestingly, a history of bone fractures has
been reported to be associated with increased MBC risk,
possibly because of alterations in the bio-available ratio of
estrogen to testosterone [33].
It is noteworthy that ESR1 has been recently associated
with the risk of triple negative BCs in women [29]. While
we did not observe this association in our MBC series, on
the other hand, we could observe that the highest per-
centage of the risk genotype of ESR1 was present in the
small subgroup of MBCs represented by HER2? (ER-,
PR- HER2?) tumor subtype. Intriguingly, we have
recently shown that HER2? subtype was associated with
BRCA2 mutations in MBC [10]. Although based on small
number of cases, these results may suggest that the
observed associations between susceptibility loci and ER/
PR status may reflect underlying associations with partic-
ular molecular profiles.
Overall, when combined with data in FBC, our results
suggest that ESR1 may be specifically associated with ER-
BCs. Since ESR1 gene encodes estrogen receptor a (ERa)
that regulates signal transduction of estrogens, it is
tempting to speculate that inherited variation may affect
ESR1 expression and promote formation of ER- tumors.
Compared to ER? BCs, ER- BCs are quite infrequent,
thus our results may shed some light on the genetic pre-
disposition to this rare BC subtype that represents a chal-
lenge in the clinical setting.
Although we had overall a large sample size, a potential
limitation of our study was that information on tumor
characteristics was not available for all cases. In addition,
these data had been predominantly abstracted from medical
records, rather than being obtained through a standardized
pathology review. Missing data are likely to be indepen-
dent of susceptibility loci, and thus would tend to under-
estimate associations rather than lead to spurious
associations. However, the strong associations with ER
status suggest that this effect was minimal, at least for the
features examined here.
Overall, our data, based on a large and well-character-
ized MBC series, add to the accumulating evidence that
common low-penetrance BC susceptibility alleles, partic-
ularly at ESR1 and TOX3 loci, play a role in MBC sus-
ceptibility and, interestingly, indicate that ESR1 may be
associated with distinct tumor subtypes defined by ER
negative status in men.
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